Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (3015)	12/3/1997 3:37:00 PM
From: Brian Pastor	Read Replies (1) \| Respond to of 23519

Someone is accumulating alot of the December 27.5 calls. I am long on the stock and hope this a bull bet, but can't tell. it could be a short hedging against a squeeze, but it seems a bit far out for that. If it were a short term short play, I'd assume the 25 calls for protection not the thirty. Who knows. Would like to see a nice bounce to 25 in short order, but I will not be a weak hand with my shares becasue we all know that there will be a run to 31 in Jan in anticipation of earnings.

To: RT who wrote (3015)	12/3/1997 3:38:00 PM
From: Web2	Respond to of 23519

A Repost from MCHM thread(FWIW). Tuesday, Dec 2 1997 9:54PM EST Reply # of 309 Ellen: Here is the text of a Dow Jones news article I found by searching the WSJ tonight. Dow Jones Newswires -- December 2, 1997 Warrants Could Be Behind 15% MacroChem Stock Drop By PAULA L. STEPANKOWSKY Dow Jones Newswires LONGVIEW, Wash. -- The pending expiration of a number of outstanding warrants could be behind a double-digit drop in the price of MacroChem Corp. (MCHM) stock Tuesday, said a spokeswoman for the Lexington, Mass.-based pharmaceutical company. MacroChem shares closed at 6 9/16, down 1 1/8, or 14.6% on volume of 743,700, compared with a daily average of 315,400. Director of Investor Relations Jerri DeKriek said the company has no news to report that could move the stock price, but that the outstanding warrants, which expire before Dec. 15, could be playing a role. "We believe people are exercising the warrants," she said. "The fundamentals of the company haven't changed." Analyst Jeff Berg, of M. H. Meyerson in Jersey City, N.J., also said he knew of no news that would cause MacroChem stock to drop sharply, but did note that competitor Vivus Inc. (VVUS), of Menlo Park, Calif., received approval Monday to market its insertion impotency product in England. Still, Vivus shares also closed down - falling 13/16, or 3.5%, to 22 5/8 on volume of 635,300, compared with a daily average of 1.5 million. Jay Abella, biotech analyst for Westergaard Micro-Cap Online in Williamsburg, Va., said the drop in MacroChem's stock price could also be due to year-end tax-loss selling. MacroChem's DeKriek said the company hopes to have some good news shortly regarding Food and Drug Administration Phase 2B trials on its topical gel treatment for male impotency. "Since we're relying on the labs to provide results, we don't know what the timeframe is," she said. -By Paula L. Stepankowsky; paula.stepankowsky@cor.dowjones.com ------------------------------------------------------------------------ Current quote for: MCHM \| VVUS Return to top of page Copyright c 1997 Dow Jones & Company, Inc. All Rights Reserved. Bill